Hepatorenal Syndrome
AKI in cirrhosis after excluding other causes. Kidneys are structurally normal but functionally failing due to splanchnic vasodilation → systemic underfilling → renal vasoconstriction. Diagnosis of exclusion. Terlipressin FDA-approved 2022. Liver transplant is the only cure.
🔍 Overview
Definition & Classification
- HRS-AKI (formerly Type 1): Rapid Cr rise > 0.3 mg/dL in 48h or doubling of Cr within 7 days. Median survival 2 weeks without treatment.
- HRS-CKD (formerly Type 2): Gradual, stable Cr elevation. Often associated with refractory ascites.
Pathophysiology
- Portal hypertension → splanchnic vasodilation (nitric oxide, other vasodilators)
- → Effective arterial underfilling → activation of RAAS, sympathetic nervous system, ADH
- → Renal vasoconstriction → decreased GFR
- → Kidneys are structurally normal but functionally failing
- If you transplant these kidneys into a healthy person, they work perfectly
HRS is a diagnosis of EXCLUSION. You MUST rule out: hypovolemia (albumin challenge), ATN (urine Na > 40, muddy brown casts), obstruction (ultrasound), nephrotoxic drugs. If FENa < 1% and bland UA → think HRS.
🚨 Management
Stepwise Approach
Step 1 -Stop nephrotoxins
STOP all nephrotoxic meds, diuretics, beta-blockers, NSAIDs, ACEi/ARBs. These worsen renal perfusion.
Step 2 -Albumin challenge
Albumin 1 g/kg (max 100g) IV × 2 days. Rule out pre-renal AKI. If no Cr improvement → HRS.
Step 3 -Triple therapy (classic)
Midodrine (ProAmatine) 7.5–12.5 mg PO TID + Octreotide (Sandostatin) 100–200 mcg SQ TID + Albumin 25–50g IV daily. Splanchnic vasoconstriction + volume expansion.
Step 4 -Terlipressin (preferred if available)
Terlipressin (Terlivaz) 0.5–1 mg IV q6h + albumin. FDA-approved 2022 based on CONFIRM, 2021. First drug specifically approved for HRS.
Step 5 -TIPS
Transjugular intrahepatic portosystemic shunt -reduces portal pressure. Consider if appropriate candidate.
Definitive -Liver transplant
Liver transplant is the only cure. HRS often resolves after successful transplant because the underlying portal hypertension is corrected.
🧪 Workup
| Test | Expected in HRS | Purpose |
|---|---|---|
| BMP | ↑ Cr, ↑ BUN | Baseline and trending renal function |
| UA with microscopy | Bland (no casts, no cells) | ATN has muddy brown casts; GN has RBC casts |
| Urine Na | < 10 mEq/L | Very low urine Na = avid renal sodium retention |
| FENa | < 1% | Pre-renal physiology (kidneys structurally normal) |
| Renal ultrasound | Normal kidneys | Rule out obstruction |
| Hepatic panel, INR, albumin | Deranged (cirrhosis) | Confirm underlying liver disease severity |
| Diagnostic paracentesis | Rule out SBP | SBP is a common trigger for HRS |
💊 Medications
| Drug | Dose | Mechanism / Notes |
|---|---|---|
| Midodrine (ProAmatine) | 7.5–12.5 mg PO TID | Alpha-1 agonist → splanchnic vasoconstriction |
| Octreotide (Sandostatin) | 100–200 mcg SQ TID | Inhibits splanchnic vasodilation |
| Albumin 25% | 25–50 g IV daily | Volume expansion + oncotic pressure support |
| Terlipressin (Terlivaz) | 0.5–1 mg IV q6h | Vasopressin analog. FDA-approved for HRS 2022. Preferred over triple therapy if available. |
| Norepinephrine | 0.5–3 mcg/kg/min IV drip | ICU alternative to midodrine/octreotide. More potent vasoconstrictor. |
📋 On Rounds
Pimp Questions
What is the pathophysiology of hepatorenal syndrome?
Portal hypertension → splanchnic vasodilation (mediated by nitric oxide and other vasodilators) → effective arterial underfilling → baroreceptor-mediated activation of RAAS, sympathetic nervous system, and ADH → intense renal vasoconstriction → decreased GFR. The kidneys are structurally normal -if transplanted into a healthy recipient, they work perfectly. This is why liver transplant cures HRS.
Why do we give an albumin challenge before diagnosing HRS?
To rule out pre-renal AKI (hypovolemia). Cirrhotics are often volume-depleted from diuretics, GI losses, or poor intake. Albumin 1 g/kg (max 100g) × 2 days provides a structured volume challenge. If creatinine improves → it was pre-renal, not HRS. If no improvement despite adequate volume → diagnosis of HRS is supported. This step is required by diagnostic criteria.
What's new about terlipressin?
Terlipressin (Terlivaz) was FDA-approved in 2022 as the first drug specifically approved for HRS. The CONFIRM trial showed terlipressin + albumin improved verified HRS reversal vs placebo + albumin. Key safety concern: respiratory adverse events, especially in patients who are volume overloaded. Must monitor closely for pulmonary edema.
Why stop beta-blockers in HRS?
Beta-blockers (nadolol, propranolol, carvedilol) reduce cardiac output in cirrhotics who are already hemodynamically compromised. In the setting of HRS, the heart needs to maximize output to compensate for splanchnic vasodilation. Beta-blockers blunt this compensatory response → further reduction in effective arterial volume → worsening renal perfusion.
Clinical Examples
📋 Case 1, HRS-AKI After SBP
Patient: 58M with decompensated cirrhosis (Child-Pugh C), recently treated for SBP. Despite antibiotics and albumin, Cr rising from 1.2 to 3.8 over 4 days. UOP declining.
Key findings: Bland UA (no casts, no proteinuria). FENa < 1%. Urine Na < 10. No nephrotoxin exposure. No response to albumin challenge (1 g/kg x 2 days). Renal US normal.
Management:
- Stop diuretics, beta-blockers, NSAIDs, and all nephrotoxins
- Start midodrine 7.5 mg PO TID + octreotide 100 mcg SQ TID + albumin 25-50g IV daily
- Consider terlipressin if available (FDA-approved 2022) CONFIRM Trial
- Hepatology and transplant evaluation, liver transplant is the only definitive cure
- Monitor for volume overload (terlipressin risk: respiratory events)
Teaching point: SBP is the most common precipitant of HRS. The kidneys in HRS are structurally normal, if transplanted to a healthy recipient, they work perfectly. The problem is splanchnic vasodilation causing renal vasoconstriction.
📋 Case 2, Differentiating HRS from ATN
Patient: 51F with cirrhosis, admitted with GI bleed and hypotension. Received NS resuscitation. Cr rising from 0.9 to 2.4. UA shows muddy brown casts.
Key findings: FENa 3.2%. Urine Na 45 mEq/L. Muddy brown granular casts on UA. This is ATN from hypoperfusion during the bleed, NOT HRS.
Management:
- Supportive care, ATN typically recovers with time
- Avoid further nephrotoxins (no contrast, no NSAIDs, no aminoglycosides)
- Continue volume resuscitation as needed for the GI bleed
- Monitor Cr trend, ATN typically peaks in 7-10 days then recovers
Teaching point: HRS = FENa < 1%, urine Na < 10, bland UA. ATN = FENa > 2%, urine Na > 20, muddy brown casts. This distinction is critical because HRS requires vasoconstrictor therapy while ATN is managed supportively.
📋 Case 3, Terlipressin for HRS-AKI
Patient: 62M with NASH cirrhosis, MELD 32. Cr 4.2, rising despite albumin challenge. Diagnosed with HRS-AKI. Listed for liver transplant but unlikely to receive organ in time.
Key findings: Failed albumin challenge. No other cause of AKI identified. Hemodynamically: MAP 58, tachycardic. Volume status euvolemic by exam.
Management:
- Terlipressin 0.5 mg IV q6h (titrate up to 2 mg q6h if Cr not improving) + albumin CONFIRM Trial
- Monitor closely for respiratory adverse events (pulmonary edema), key safety concern
- Daily Cr, urine output, volume status assessment
- TIPS consideration as bridge to transplant in select patients
- Dialysis if refractory hyperkalemia, acidosis, or volume overload develops
Teaching point: Terlipressin (FDA-approved 2022) is the first drug specifically approved for HRS. It is a vasopressin analog that causes splanchnic vasoconstriction, redirecting blood flow to the kidneys. Key safety concern: respiratory events, especially in volume-overloaded patients.
Monitoring
| Parameter | Frequency | Target / Action |
|---|---|---|
| Creatinine | Daily (q12h if ICU) | Trending improvement = therapy working. No response by 48–72h → escalate. |
| Urine output | Strict I&Os | UOP > 0.5 mL/kg/hr. Oliguria common in HRS. |
| MAP | Continuous or q4h | Target MAP > 65–70. Midodrine/terlipressin should improve MAP. |
| Daily weights | Daily | Fluid balance assessment |
| Hepatic panel | Daily | Underlying liver disease trajectory |
⚡ Summary
The Kidneys Are Not the Problem
Splanchnic vasodilation from portal hypertension underfills the systemic circulation, so the kidney vasoconstricts even though it is structurally normal. That is why a biopsy would look unremarkable and why an HRS kidney transplanted into someone else recovers: the lesion is hemodynamic, not parenchymal.
It Is a Diagnosis of Exclusion
Rule out hypovolemia, acute tubular necrosis, obstruction and nephrotoxins before calling it HRS. The pattern that fits is a bland urinalysis, urine sodium below 10 mEq/L and FENa below 1%, with a normal renal ultrasound. Muddy brown casts and a urine sodium above 40 mean ATN, and treating that with vasoconstrictors helps nobody.
The Albumin Challenge Is Both Test and Treatment
Albumin 1 g/kg daily (up to 100 g) for 2 days with all diuretics stopped. Creatinine that improves means the patient was volume-depleted, not in HRS; creatinine that does not improve supports the diagnosis. This step is mandatory before committing to vasoconstrictor therapy.
Stop What Is Making It Worse
Hold diuretics, NSAIDs, aminoglycosides, ACE inhibitors and ARBs, and hold off on contrast. Beta blockers given for varices should be held in refractory ascites and HRS, because the loss of cardiac output reserve worsens renal perfusion in a patient who has none to spare.
Treat With a Vasoconstrictor Plus Albumin
Terlipressin plus albumin is FDA-approved (2022) and is the preferred regimen, with roughly a third of patients achieving HRS reversal. Midodrine 7.5 to 12.5 mg TID plus octreotide 100 to 200 mcg SC TID plus albumin is the outpatient or non-ICU alternative and is considerably less effective. Norepinephrine plus albumin is equivalent to terlipressin in the ICU. Albumin is not optional: it is what restores effective circulating volume so the vasoconstrictor has something to squeeze.
Watch for Terlipressin's Two Harms
Ischemic complications, in the gut, digits and myocardium, so avoid it in known ischemic disease. Respiratory failure, driven by the volume load, which is why it is avoided when ACLF is grade 3 or the patient is already hypoxemic. Monitor oxygenation daily rather than only at the start.
Transplant Is the Only Cure
Everything else is a bridge. Refer for liver transplant evaluation at the time of diagnosis, not after therapy fails: HRS marks end-stage liver disease with a survival measured in weeks to months untreated. Dialysis is a bridge to transplant, not a destination, and offers little to a patient who is not a candidate.
Prevent It Where You Can
Albumin with large-volume paracentesis (8 g per liter removed above 5 liters) prevents post-paracentesis circulatory dysfunction. Albumin plus antibiotics in spontaneous bacterial peritonitis (1.5 g/kg on day 1, 1 g/kg on day 3) cuts HRS and mortality. SBP is the commonest precipitant, so a diagnostic tap is part of the workup of every cirrhotic with a rising creatinine.
Related Topics
Acute Alcoholic HepatitisAcute Liver FailureAutoimmune HepatitisBowel ObstructionCholangitis & CholecystitisCirrhosis & Ascites